New drug shows promise for repairing damaged hearts in stable heart failure patients

NCT ID NCT07405944

Recruiting now Disease control Sponsor: University Medical Centre Ljubljana Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether the drug vericiguat can help repair the hearts of adults with stable heart failure with reduced ejection fraction (HFrEF). Researchers will compare people taking vericiguat plus standard care to those on standard care alone, measuring changes in heart structure and function over 12 months. The study involves 60 participants and includes blood tests, heart scans, and glucose tests to understand how the drug works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure Fibrosis Inflammation Insulin Resistance systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEART FAILURE HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF)

Contacts and locations

Locations

University Medical Centre Ljubljana
RECRUITING

Ljubljana, 1000, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.